Next on tap for Meridian Bioscience‘s (NASDAQ:VIVO) illumigene molecular diagnostic testing platform is a test for Mycoplasma pneumonia, an infection of the lungs. The illumigene Mycoplasma test is ...

Meridian Bioscience has filed an application for federal regulatory approval of a next-generation molecular test that detects a type of bacteria that causes damage to the digestive system. Meridian’s ...

illumigene® Malaria is more widely used than it was a year ago, but Meridian Bioscience says even more countries should use it." Researchers in Europe and philanthropists in New York are singing the ...

Diagnostic test kit maker Meridian Bioscience (VIVO) has won the approval of the U.S. Food and Drug Administration (:FDA) for its new test for detection of Legionnaire’s disease (legionellosis), a ...

Meridian Bioscience (VIVO) is a $900 million provider of diagnostic test kits for gastrointestinal and respiratory infectious diseases. The company is expected to grow sales 18% this year to $300 ...

Newtown-based Meridian Bioscience is deploying its newly developed test illumigene® Malaria in Dakar, Senegal and planning a rollout of this potentially life-saving diagnostic across Africa. A test ...